Sandra Heskamp studied Biomedical Sciences at the Radboud University of Nijmegen. In 2009, she graduated in two master’s: Epidemiology and Biostatistics and Human Pathobiology. That same year she started her PhD project Molecular imaging of receptor tyrosine kinases in cancer at the Department of Radiology and Nuclear Medicine of the Radboud university medical center in Nijmegen. During her PhD research, she developed new radiotracers for radionuclide imaging of receptor tyrosine kinases in cancer. Since 2012, she also participates in a European consortium (Innovative Medicines Initiative, EU Directive 2010/63/EU) that investigated the potential of diffusion weighted MRI and 18F-FLT PET as early biomarkers of treatment response in cancer. In addition, she performed an internship at the Technical University Munich to study the potential of pretargeted radioimmunotherapy using the alpha emitter bismuth-2013 (July – September 2013). She obtained her PhD in June 2014. Currently, she works as a post-doc in the TRACER group and her research focuses on novel pretargeting approaches for imaging and treatment of cancer, imaging of immune checkpoint inhibitors like PD-L1, and imaging of prostate cancer with PSMA ligands.